KR950701634A - 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸 아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체(Novel Mercaptoacetylamido Pyridazo[1,2]Pyridazine, Pyrazolo[1,2]Pyridazine, Pyridazo[1,2-a][1,2]Diazepine and Pyrazdo[1,2-a][1,2]Diazepine Derivatives Useful as Inhibitors of Enkephalinase and ACE) - Google Patents

엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸 아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체(Novel Mercaptoacetylamido Pyridazo[1,2]Pyridazine, Pyrazolo[1,2]Pyridazine, Pyridazo[1,2-a][1,2]Diazepine and Pyrazdo[1,2-a][1,2]Diazepine Derivatives Useful as Inhibitors of Enkephalinase and ACE)

Info

Publication number
KR950701634A
KR950701634A KR1019940704065A KR19940704065A KR950701634A KR 950701634 A KR950701634 A KR 950701634A KR 1019940704065 A KR1019940704065 A KR 1019940704065A KR 19940704065 A KR19940704065 A KR 19940704065A KR 950701634 A KR950701634 A KR 950701634A
Authority
KR
South Korea
Prior art keywords
compound
oxo
diazepine
pyridazo
pyridazine
Prior art date
Application number
KR1019940704065A
Other languages
English (en)
Other versions
KR100281450B1 (ko
Inventor
개리 에이. 플린
패트릭 더블유 셤
Original Assignee
스티븐 엘. 네스비트
메렐 댜우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 엘. 네스비트, 메렐 댜우 파마슈티칼스 인크. filed Critical 스티븐 엘. 네스비트
Publication of KR950701634A publication Critical patent/KR950701634A/ko
Application granted granted Critical
Publication of KR100281450B1 publication Critical patent/KR100281450B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 엔케팔리나제 및 ACE 억제제로서 유용한 하기 일반식(Ⅰ)의 특정신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀에 관한 것이다.

Description

엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸 아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리디진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체(Novel Mercaptoacetylamido Pyridazo[1,2]Pyridazine, Pyrazolo[1,2]Pyridazine, Pyridazo[1,2-a][1,2]Diazepine and Pyrazdo[1,2-a][1,2]Diazepine Derivatives Useful as Inhibitors of Enkephalinase and ACE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (29)

  1. 하기 일반식의 화합물 및 그의 제약적으로 허용되는 염 및 각각의 광학 이성질체.
    상기 식 중, B는 메틸렌, 에틸렌 또는 비닐렌기이고, R1은 수소, C1-C8알킬, -CH2OCH2CH2OCH3또는 Ar-Y-기이고, R2는 수소, 아세틸, -CH2O-C(O)C(CH3)3또는 벤조일이고, R3은 카르복실, 알콕시카르보닐 또는 Ar-Y-O-카르보닐기이고, R4및 R5는 각각 수소 원자이거나, 또는 R4및 R5는 함께 옥소기이고, n은 0, 1 또는 2이다.
  2. 제1항에 있어서, n은 2인 화합물.
  3. 제2항에 있어서, B은 에틸렌기인 화합물
  4. 제3항에 있어서, R1은 페닐메틸인 화합물.
  5. 엔케팔리나제 억제 유효량의 하기 일반식의 화합물 및 그의 제약학적으로 허용되는 염 및 각각의 광학이성질체를 엔케팔리나제 억제를 필요하 하는 환자에게 투여하는 것으로 이루어지는 상기 환자의 엔케팔리나제 억제 방법.
    상기 식 중, B는 메틸렌, 에틸렌 또는 비닐렌기이고, R1은 수소, C1-C8알킬, -CH2OCH2CH2OCH3또는 Ar-Y-기이고, R2는 수소, 아세틸, -CH2O-C(O)C(CH3)3또는 벤조일이고, R3은 카르복실, 알콕시카르보닐 또는 Ar-Y-O-카르보닐기이고, R4및 R5는 각각 수소 원자이거나, 또는 R4및 R5는 함께 옥소기이고, n은 0, 1 또는 2이다.
  6. 제5항에 있어서, 상기 환자는 엔도르핀 또는 엔케팔린에 의해 매개되는 진통 효과를 필요로 하는 환자인 방법.
  7. 제5항에 있어서, 상기 환자는 ANP에 의해 매개되는 저혈압 효과를 필요로 하는 환자인 방법.
  8. 제5항에 있어서, 상기 환자는 ANP에 의해 매개되는 이뇨 효과를 필요로 하는 환자인 방법.
  9. 제5항에 있어서, 상기 환자는 울혈성 심장 마비 환자인 방법.
  10. ACE 억제 유효량의 하기 일반식의 화합물 및 그의 제약학적으로 허용되는 염 및 각각의 광학 이성질체를 ACE 억제를 필요로 하는 환자에게 투여하는 것으로 이루어지는 상기 환자의 ACE 억제 방법.
    상기 식 중, B는 메틸렌, 에틸렌 또는 비닐렌기이고, R1은 수소, C1-C8알킬, -CH2OCH2CH2OCH3또는 Ar-Y-기이고, R2는 수소, 아세틸, -CH2O-C(O)C(CH3)3또는 벤조일이고, R3은 카르복실, 알콕시카르보닐 또는 Ar-Y-O-카르보닐기이고, R4및 R5는 각각 수소 원자이거나, 또는 R4및 R5는 함께 옥소기이고, n은 0, 1 또는 2이다.
  11. 제10항에 있어서, 상기 환자는 저혈압 효과를 필요로 하는 환자인 방법.
  12. 제10항에 있어서, 상기 환자는 인식 증진 효과를 필요로 하는 환자인 방법.
  13. 제10항에 있어서, 상기 환자는 울혈성 심장 마비 환자인 방법.
  14. 불활성 담체와 혼합 또는 회합된 분석 가능한 양의 제1항의 화합물로 이루어지는 조성물.
  15. 1종 이상의 제약학적으로 허용되는 담체 또는 부형제와 혼합 또는 회합된 면역 억제 유효량의 제1항의 화합물로 이루어지는 제약 조성물.
  16. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(R)-아세틸티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산인 것인 화합물.
  17. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(R)-티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산인 것인 화합물.
  18. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-아세틸티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산인 것인 화합물.
  19. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산인 것인 화합물.
  20. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-아세틸티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산t-부틸에스테르인 것인 화합물.
  21. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산 t-부틸 에스테르인 것인 화합물.
  22. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-아세틸티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(R)-카르복실산 t-부틸 에스테르인 것인 화합물.
  23. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(R)-카르복실산 t-부틸 에스테르인 것인 화합물.
  24. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-아세틸티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(R)-카르복실산인 것인 화합물.
  25. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-티오-3-페닐프로필)아미노]-옥타히드로-10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(R)-카르복실산인 것인 화합물.
  26. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-아세틸티오-3-페닐프로필)아미노]-옥타히드로-6,10-디옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산 t-부틸 에스테르인 것인 화합물.
  27. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-아세틸티오-3-페닐프로필)아미노]-옥타히드로-6,10-디옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산인 것인 화합물.
  28. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-티오-3-페닐프로필)아미노]-옥타히드로-6,10-옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산 t-부틸 에스테르인 것인 화합물.
  29. 제1항에 있어서, 상기 화합물은 9-[(S)-(1-옥소-2(S)-티오-3-페닐프로필)아미노]-옥타히드로-6,10-디옥소-6H-피리다조[1,2-a][1,2]디아제핀-1(S)-카르복실산 t-부틸 에스테르인 것인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940704065A 1992-05-15 1993-04-21 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체 KR100281450B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US88496392A 1992-05-15 1992-05-15
US884,963 1992-05-15
US884963 1992-05-15
US4000393A 1993-04-09 1993-04-09
US040,003 1993-04-09
US40003 1993-04-09
PCT/US1993/003721 WO1993023403A1 (en) 1992-05-15 1993-04-21 NOVEL MERCAPTOACETYLAMIDO PYRIDAZO[1,2]PYRIDAZINE, PYRAZOLO[1,2]PYRIDAZINE, PYRIDAZO[1,2-a][1,2]DIAZEPINE AND PYRAZOLO[1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE

Publications (2)

Publication Number Publication Date
KR950701634A true KR950701634A (ko) 1995-04-28
KR100281450B1 KR100281450B1 (ko) 2001-02-01

Family

ID=26716641

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940704065A KR100281450B1 (ko) 1992-05-15 1993-04-21 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체

Country Status (19)

Country Link
US (1) US5366973A (ko)
EP (1) EP0640086B1 (ko)
JP (1) JP3360079B2 (ko)
KR (1) KR100281450B1 (ko)
AT (1) ATE182892T1 (ko)
AU (1) AU669364B2 (ko)
CA (1) CA2133963C (ko)
DE (1) DE69325904T2 (ko)
DK (1) DK0640086T3 (ko)
ES (1) ES2138622T3 (ko)
FI (1) FI108230B (ko)
GR (1) GR3031287T3 (ko)
HU (1) HU223663B1 (ko)
IL (1) IL105680A (ko)
MX (1) MX9302824A (ko)
NO (1) NO302573B1 (ko)
NZ (1) NZ251930A (ko)
TW (1) TW270115B (ko)
WO (1) WO1993023403A1 (ko)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646276A (en) * 1992-05-13 1997-07-08 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
NZ267161A (en) * 1993-06-11 1996-12-20 Eisai Co Ltd Dipeptidic benzazepine derivative with ace inhibiting activity
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
CN1069317C (zh) * 1994-02-14 2001-08-08 默里尔药物公司 用作脑啡肽酶抑制剂的新的1,2－二氢化茚－2－巯基乙酰胺二硫化物衍生物
WO1995021857A1 (en) * 1994-02-14 1995-08-17 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
EP0750631B1 (en) * 1994-02-14 2000-04-05 Merrell Pharmaceuticals Inc. Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
JPH09510476A (ja) * 1994-03-24 1997-10-21 メリル・フアーマシユウテイカルズ・インコーポレイテツド 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のアミノアセチルメルカプト誘導体
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US6699869B1 (en) 1995-03-24 2004-03-02 Myriad Genetics Inc. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US6020331A (en) 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6245764B1 (en) 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5877313A (en) * 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
CA2319766A1 (en) * 1998-02-12 1999-08-19 Molecumetics Ltd. .beta.-sheet mimetics and methods relating to the use thereof
IT1298268B1 (it) * 1998-02-18 1999-12-20 Zambon Spa Procedimento per la preparazione dell'acido (s)-2-bromo-3-fenil- propionico
FR2777889B1 (fr) * 1998-04-27 2004-07-09 Hoechst Marion Roussel Inc Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs
PT1087775E (pt) 1998-06-17 2005-11-30 Bristol Myers Squibb Co Prevencao de enfarte cerebral por administracao de uma combinacao de farmacos antiplaquetarios bloqueadores de receptores de adp e anti-hipertensivos
US6177565B1 (en) * 1998-08-19 2001-01-23 Vertex Pharmaceuticals Inc. Process for synthesizing piperazic acid
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
AU2002348276A1 (en) * 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
WO2003068237A1 (en) 2002-02-14 2003-08-21 Myriad Genetics, Inc. Beta-sheet mimetics and composition and methods relating thereto
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
EP1906934A4 (en) * 2005-07-14 2012-03-07 Franco Folli DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CA2646598C (en) 2006-03-21 2014-08-19 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
EA200870575A1 (ru) 2006-05-26 2009-08-28 Амилин Фармасьютикалз, Инк. Композиции и способы лечения застойной сердечной недостаточности
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN102149710A (zh) 2008-06-24 2011-08-10 百时美施贵宝公司 糖皮质激素受体、AP-1和/或NF-κB 活性的环戊噻吩调节剂及其用途
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN106674228B (zh) * 2016-12-09 2018-12-04 河南农业大学 多元杂环化合物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3334095A (en) * 1965-02-16 1967-08-01 Sandoz Ag Novel pyrrolo-oxazines and pyrrolo-oxazoles
US3334091A (en) * 1965-03-25 1967-08-01 Sandoz Ag Sedatives
GB1525845A (en) * 1976-07-30 1978-09-20 Ucb Sa 1,2,4,5-tetrahydro-3h-2-benzazepin-3-ones
IE50839B1 (en) * 1980-02-26 1986-07-23 Wyeth John & Brother Ltd Novel processes for preparing proline derivatives and analogous compounds
EP0042100A1 (de) * 1980-06-13 1981-12-23 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pyrazolopyridazin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung, sowie diese enthaltende Arzneimittel
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
ZA833214B (en) * 1982-05-12 1983-12-28 Hoffmann La Roche Bicyclic compounds
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4552889A (en) * 1983-06-09 1985-11-12 Eli Lilly And Company 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
US4692438A (en) * 1984-08-24 1987-09-08 Hoffmann-La Roche Inc. Pyridazo-diazepines, diazocines, and -triazepines having anti-hypertensive activity
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
EP0202046B1 (en) * 1985-04-30 1991-01-30 Eli Lilly And Company 7-substituted bicyclic pyrazolidinones
CA1337654C (en) * 1986-06-13 1995-11-28 Gary A. Flynn Fused tricyclic lactams as antihypertensive agents
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
US4973585A (en) * 1986-06-13 1990-11-27 Merrell Dow Pharmaceuticals Tricyclic lactams active as antihypertensive agents
GB8629875D0 (en) * 1986-12-15 1987-01-28 Hoffmann La Roche Pyridazodiazepine derivatives
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use
GB8926512D0 (en) * 1989-11-23 1990-01-10 Pfizer Ltd Therapeutic agents
US5407960A (en) * 1989-12-22 1995-04-18 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
ATE158303T1 (de) * 1990-12-21 1997-10-15 Merrell Pharma Inc Neue trizyklische amino- und nitro verbindungen mit ace-hemmenden eigenschaften
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
WO1993005809A1 (en) * 1991-09-16 1993-04-01 Schering Corporation Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating or preventing myointimal proliferation

Also Published As

Publication number Publication date
IL105680A (en) 1998-01-04
WO1993023403A1 (en) 1993-11-25
CA2133963A1 (en) 1993-11-25
DE69325904D1 (de) 1999-09-09
JPH07506832A (ja) 1995-07-27
DE69325904T2 (de) 1999-12-09
CA2133963C (en) 1998-07-07
ATE182892T1 (de) 1999-08-15
FI945363A0 (fi) 1994-11-14
FI108230B (fi) 2001-12-14
TW270115B (ko) 1996-02-11
EP0640086B1 (en) 1999-08-04
NO944335D0 (no) 1994-11-14
AU4033293A (en) 1993-12-13
MX9302824A (es) 1994-05-31
GR3031287T3 (en) 1999-12-31
EP0640086A1 (en) 1995-03-01
KR100281450B1 (ko) 2001-02-01
HUT71099A (en) 1995-11-28
JP3360079B2 (ja) 2002-12-24
HU223663B1 (hu) 2004-11-29
ES2138622T3 (es) 2000-01-16
AU669364B2 (en) 1996-06-06
FI945363A (fi) 1994-11-14
DK0640086T3 (da) 1999-12-06
NO944335L (no) 1995-01-13
NZ251930A (en) 1996-02-27
NO302573B1 (no) 1998-03-23
US5366973A (en) 1994-11-22
IL105680A0 (en) 1993-09-22

Similar Documents

Publication Publication Date Title
KR950701634A (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 신규 메르캅토아세틸 아미도 피리다조[1,2]피리다진, 피라졸로[1,2]피리다진, 피리다조[1,2-a][1,2]디아제핀 및 피라졸로[1,2-a][1,2]디아제핀 유도체(Novel Mercaptoacetylamido Pyridazo[1,2]Pyridazine, Pyrazolo[1,2]Pyridazine, Pyridazo[1,2-a][1,2]Diazepine and Pyrazdo[1,2-a][1,2]Diazepine Derivatives Useful as Inhibitors of Enkephalinase and ACE)
KR950701632A (ko) 4-머캅토아세틸아미노-[2]벤즈아제핀온(3) 유도체 및 엔케팔린아제 억제제로서의 이의 용도(4-Mercaptoacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors)
EA200200844A1 (ru) Ингибиторы клеточной адгезии
KR920008040A (ko) 엔케팔리나제 및 ace의 억제제로서 유용한 신규 메르캅토아세틸아미드 유도체
KR930006026A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 카르복시알킬 유도체
KR930006028A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-카르복시알킬 유도체
EA199900183A1 (ru) Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
AU645347B2 (en) Tripeptide antithrombotic agents
ATE137763T1 (de) Peptid-verbindungen, deren verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzung
EA199801047A1 (ru) Замешенные призводные инлазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
HUP0101813A2 (hu) Homo- vagy heterociklusos csoporttal helyettesített karbonsavszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
ATE125535T1 (de) Tricyclische aromatische verbindungen.
RU2003134153A (ru) Дипептиды, содержащие на n-концевом аминокислотном остатке 2-тиоацильную группу, в качестве ингибиторов вазопептидазы
EA199800882A1 (ru) Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно)
KR950704349A (ko) 엔케팔리나제 및 안지오텐신 전환효소 억제제로서 유용한 신규한 머캅토아세틸아미드 비사이클릭 락탐 유도체(Novel mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ACE)
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
IE893204L (en) N-imidazolyl- and n-imidazolylmethyl-derivatives of¹substituted bicyclic compounds
EA200200663A1 (ru) НОВЫЕ СОЕДИНЕНИЯ ОКТАГИДРО-2H-ПИРИДО[1,2-α]ПИРАЗИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ИХ СОДЕРЖАЩИЕ
AU1006992A (en) New derivatives of 1,4-dihydropyridine,their preparation procedure and therapeutic compositions containing them
KR940701407A (ko) 레닌 억제제로서의 하이드록시아지도 유도체 및 관련 화합물
EA200401011A1 (ru) Новые соединения аминокислоты, способ их получения и фармацевтические композиции, содержащие их
DK216186D0 (da) Hexensyrer
KR900012934A (ko) 피리도 피리미딘 유도체, 이들을 함유하는 약학적 조성물 및 이들을 제조하는 제조방법
ES2040629A1 (es) Procedimiento de obtencion de derivados triciclicos de la benzotiazepina farmacologicamente activos.
IE873474L (en) Dibenzo£be|oxepinacetic acid derivatives, their preparation¹and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20041109

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee